#CAPSY STUDY CODE#
#CAPSY STUDY TRIAL#

Lastly, the most complex part of the design was the boundary between the atrium and the lab spaces. Though the design and installation requirements for these closely spaces sprinklers are quite rigid, it was determined that this was the significantly more cost-effective and aesthetically desirable than the use of rated glass partitions. These sprinklers are installed within 4 to 12 inches of the glass they are protecting. The glass doors along the boundary were specified to be self-closing and gypsum soffits were provided along the glass boundary so that concealed pendent sprinklers could be spaced every 6 feet along the boundary.

#CAPSY STUDY CODE#

The remainder of the separation between the spaces was provided by the standard fire-resistance rated fire barriers, with no need for additional protection by the automatic sprinkler system.įor the separation between nonatrium and atrium regions encompassed within control area 1, the closely spaced sprinkler rule detailed by International Building Code Section 404.6, Exception 1 was applied. The glass doors were required to be made of rated glass because window sprinklers cannot be used for operable openings. The boundary between these two spaces did not consist of any glass paneling with the exception of a few glass doors. The most basic part of the design for this space was the fire-resistance rated separation between control areas 2 and 3. It was determined early in the building design that the use of sprinklers would be used where possible in lieu of common passive fire protection measures to achieve the required fire resistance ratings. A significant reduction in the frequency of ventricular premature depolarizations (p = 0.004) occurred in the first few weeks of 'therapy' with a further significant (p less than 0.04) decrease between 3 to 12 months.The presence of an atrium and multiple control areas in the building, compounded by the vast amount of glass paneling, made this a complex situation from a life safety and fire protection standpoint. In the CAPS placebo group, 19% developed some serious clinical event in 1 year (death, heart failure, proarrhythmia) that could be attributable to antiarrhythmic drug toxicity. Patient compliance and follow-up in a post myocardial infraction setting can be maintained.Įfficacy rates higher with encainide (70%) and flecainide (83%) than with imipramine (52%) and moricizine (66%) or placebo (37%) (p = 0.01).Įncainide, flecainide, moricizine more effective than placebo (p = 0.001).Īdverse effects seen lower with encainide and flecainide than with imipramine, moricizine or placebo.

#CAPSY STUDY TRIAL#

It is possible to identify and recruit patients for a definitive trial of post MI antiarrhythmias.Īgents capable of suppressing VPDs post infarct exist and seem well tolerated. Patient compliance with treatment routines Drug/Procedures Used: LVEF 10 consecutive VPDs at a rate > 100/min (disqualifying VT) Primary Endpoints:Įfficacy ( > 70% reduction in VPD and > 90% suppression of VPD runs) of different antiarrhythmic agents studied. Geographic or social factors making study participation impracticalĪge 10 VPD/hr or > five episodes of unsustained VT (3-9 consecutive VPD > 100 min) on 24 hour ambulatory arrhythmia monitor. Medical factors (NYHA class IV congestive heart failure, CCVS class IV angina, severe hypotension, uncorrected hypokalemia, noncardiac illness likely to shorten survival significantly to less than two years, and women of childbearing potential) Requirement of antiarrhythmic therapy (run of VT for 6 beats or more and rate of 100 bpm or more, atrial or ventricular arrhythmia that in the opinion of the treating physician required antiarrhythmic drugs other than b-blockers or digoxin), tricyclic antidepressant drugs, sotalol or phenytoin

Mean Ejection Fraction: 45% (50/min, PR interval of 220 ms or more, first-, second- or third-degree atrioventricular block, prolonged QTC interval (>480 ms), moderate or severe peripheral neuropathy, chronic or acute hepatitis, suggestion of interstitial fibrosis on chest radiographs, clinical hyperthyroidism or hypothyroidism or current therapy for these conditions

Capsy study